Modera Wealth Management LLC Sells 4,769 Shares of Amgen Inc. $AMGN

Modera Wealth Management LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.7% in the first quarter, HoldingsChannel.com reports. The fund owned 97,662 shares of the medical research company’s stock after selling 4,769 shares during the period. Modera Wealth Management LLC’s holdings in Amgen were worth $34,362,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Anfield Capital Management LLC raised its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its stake in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Amgen during the fourth quarter valued at about $26,000. Tower View Wealth Management LLC increased its position in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC raised its stake in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a report on Friday, June 5th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. UBS Group raised their target price on Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research note on Monday. BMO Capital Markets restated an “outperform” rating and issued a $400.00 target price on shares of Amgen in a research note on Wednesday, July 1st. Finally, Weiss Ratings lowered Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $356.62.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Price Performance

AMGN opened at $366.29 on Friday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market capitalization of $197.69 billion, a P/E ratio of 25.49, a P/E/G ratio of 3.76 and a beta of 0.41. The company’s 50-day simple moving average is $347.69 and its two-hundred day simple moving average is $350.38. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the business posted $4.90 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts predict that Amgen Inc. will post 22.31 EPS for the current year.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen advanced its obesity pipeline with fresh Phase 1 data on AMG 133 injection formats, which could support long-term growth if the program continues to show promise. Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
• Positive Sentiment: Amgen’s stock was highlighted in market coverage as teasing a buy point, suggesting technical traders may see room for upside if broader market conditions stabilize. Stock Market Today: Dow Sees Red While Amgen Shares Tease A Buy Point (Live Coverage)
• Neutral Sentiment: Amgen remains a candidate for another earnings beat, according to recent coverage pointing to its history of topping estimates and solid fundamentals. Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Amgen to $23.58 from $23.62 and kept a Hold rating, a modest negative for sentiment but not a major change in the outlook. Amgen Inc. (NASDAQ:AMGN) Free Report
• Negative Sentiment: Amgen halted a late-stage bemarituzumab gastric cancer trial, adding uncertainty to part of its oncology pipeline and pressuring investor expectations. Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
• Negative Sentiment: Amgen also terminated a key Phase 3 rocatinlimab eczema study, another setback that may raise concerns about the durability of its pipeline growth. Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.